- Investing.com
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
VYKAT XR Breakthrough | Explore Soleno's FDA-approved treatment for Prader-Willi Syndrome, addressing hyperphagia in a 12,000-patient U.S. market with potential global expansion |
Market Dynamics | Delve into VYKAT XR's commercial launch, pricing strategy, and early adoption metrics, with analysts projecting peak sales of up to $2.8 billion worldwide |
Financial Outlook | Discover Soleno's strong cash position of $290 million and analyst expectations of profitability, with EPS forecasts of $6.65 for FY2025 |
Analyst Consensus | Learn about the "Strong Buy" recommendation and median price target suggesting 37% upside, with targets ranging from $20 to $145 per share |
Metrics to compare | SLNO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLNOPeersSector | |
---|---|---|---|---|
P/E Ratio | −18.7x | −3.8x | −0.7x | |
PEG Ratio | 0.22 | 0.13 | 0.00 | |
Price/Book | 14.1x | 0.9x | 2.6x | |
Price / LTM Sales | 103.8x | 13.0x | 3.4x | |
Upside (Analyst Target) | 88.2% | 203.8% | 38.0% | |
Fair Value Upside | Unlock | 8.2% | 5.3% | Unlock |